Liquidia Technologies Inc. succeeded Tuesday in tossing a United Therapeutics Corp. patent covering an inhalable treatment for pulmonary arterial hypertension, when an administrative tribunal ruled the patent invalid.
The Patent Trial and Appeal Board found that US Patent No. 10,716,793, which relates to UTC’s Tyvaso product that treats high blood pressure in the lungs, was obvious in light of other inventions. Liquidia’s stock price rose 23% on Tuesday.
Tyvaso had sales of $607.5 million in 2021, 36% of UTC’s revenue and up from $483.3 million in 2020, according to data compiled by Bloomberg LP.
In an underlying district court ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.